

## Novel quinolines carrying pyridine, thienopyridine, isoquinoline, thiazolidine, thiazole and thiophene moieties as potential anticancer agents

MOSTAFA M. GHORAB<sup>1\*</sup>  
MANSOUR S. ALSAID<sup>1</sup>  
MOHAMMED S. AL-DOSARI<sup>1</sup>  
FATMA A. RAGAB<sup>2</sup>  
ABDULLAH A. AL-MISHARI<sup>3</sup>  
ABDULAZIZ N. ALMOQBIL<sup>3</sup>

<sup>1</sup> Department of Pharmacognosy  
College of Pharmacy  
King Saud University  
P.O. Box 2457, Riyadh 11451  
Kingdom of Saudi Arabia

<sup>2</sup> Pharmaceutical Chemistry Department  
Faculty of Pharmacy  
Cairo University, Cairo 11562, Egypt

<sup>3</sup> Medicinal, Aromatic and Poisonous  
Plants Research Center (MAPPRC)  
College of Pharmacy  
King Saud University, P.O. Box 2457  
Riyadh 11451, Saudi Arabia

As a part of ongoing studies in developing new anticancer agents, novel 1,2-dihydropyridine **4**, thienopyridine **5**, isoquinolines **6–20**, acrylamide **21**, thiazolidine **22**, thiazoles **23–29** and thiophenes **33–35** bearing a biologically active quinoline nucleus were synthesized. The structure of newly synthesized compounds was confirmed on the basis of elemental analyses and spectral data. All the newly synthesized compounds were evaluated for their cytotoxic activity against the breast cancer cell line MCF7. 2,3-Dihydrothiazole-5-carboxamides **27**, **25**, 4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carboxamide (**34**), 1,2-dihydroisoquinoline-7-carbonitrile (**7**), 5,6,7,8-tetrahydro-4*H*-cyclohepta[*b*]thiophene-3-carboxamide (**35**), 1,2-dihydroisoquinoline-7-carbonitrile (**6**), 2-cyano-3-(dimethylamino)-*N*-(quinolin-3-yl)acrylamide (**21**), 1,2-dihydroisoquinoline-7-carbonitriles (**11**) and (**8**) exhibited higher activity ( $IC_{50}$  values of 27–45  $\mu\text{mol L}^{-1}$ ) compared to doxorubicin ( $IC_{50}$  47.9  $\mu\text{mol L}^{-1}$ ). LQ quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**12**), 2-thioxo-2,3-dihydrothiazole-5-carboxamide (**28**) and quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**15**) show activity comparable to doxorubicin, while (quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**9**), 2,3-dihydrothiazole-5-carboxamide (**24**), thieno [3,4-*c*] pyridine-4(5*H*)-one (**5**), cyclopenta[*b*]thiophene-3-carboxamide (**33**) and (quinolin-3-yl)-6-stryl-1,2-dihydroisoquinoline-7-carbonitrile (**10**) exhibited moderate activity, lower than doxorubicin.

**Keywords:** quinolines, pyridine, thienopyridine, isoquinoline, acrylamide, thiazole, thiophene, anticancer activity

Accepted November 5, 2015  
Published online April 6, 2016

Cancer is one of the most critical health issues and is considered the second leading cause of death worldwide, just after circulatory diseases. Despite the availability of improved drugs including targeted cancer therapies, the worldwide cancer burden is expected to increase by as much as 15 million new cancer cases per year by 2020, according

\* Correspondence; e-mail: [mmsghorab@yahoo.com](mailto:mmsghorab@yahoo.com)

to the World Health Organization (WHO), unless further preventive measures are put into practice (1). Quinoline scaffold plays an important role in anticancer drug development since their derivatives have shown excellent results through different mechanisms of action such as growth inhibition by cell cycle arrest, apoptosis, inhibition of angiogenesis, disruption of cell migration and modulation of nuclear receptor responsiveness. The anticancer potential of several of these derivatives has been demonstrated on various cancer cell lines. In addition, many of quinoline derivatives are useful in diverse applications including pharmaceuticals and are today available as drugs (2). Therefore there is an urgent need to develop new classes of chemotherapeutic agents with different mechanisms of action to treat cancer (3). It has been reported that designing a single molecule with more than one pharmacophore with different modes of action could be beneficial for the treatment of cancer (4), as well as for reducing unwanted side effects (5). Many quinolines, dihydropyridines, thienopyridines, isoquinolines, acrylamides, thiazolidines, thiazoles and thiophenes were found to possess antineoplastic activity (6–11). Although the antineoplastic activity of these quinolines was attributed to intercalating binding to DNA, there were additional advantages of quinolines that interact with DNA, with a low association constant. The corresponding significant increase in the amount of free drug at equilibrium may have an important effect upon the distribution and hence the spectrum of activity and accessibility of these molecules to solid tumors (12, 13). On the other hand, a number of quinoline derivatives were reported to reverse tumor cell multidrug resistance (14, 15). Recently, it has been demonstrated that 10  $\mu\text{mol L}^{-1}$  chloroquine significantly increases cancer cell killing effects (4, 16). Several chloroquinolines (CQ) known as antimalarial drugs, such as  $N^1$ -(7-chloroquinolin-4-yl)- $N^2,N^2$ -diethylethane-1,2-diamine (**I**),  $N^1,N^1$ -diethyl- $N^2$ -(7-fluoroquinolin-4-yl)ethane-1,2-diamine (**II**),  $N$ -butyl-7-fluoroquinolin-4-amine (**III**),  $N^4$ -(7-chlo-




Fig. 1. Chemical structures of quinolines reported for anticancer activity:

**I** –  $N^1$ -(7-chloroquinolin-4-yl)- $N^2,N^2$ -diethylethane-1,2-diamine

**II** –  $N^1,N^1$ -diethyl- $N^2$ -(7-fluoroquinolin-4-yl)ethane-1,2-diamine

**III** –  $N$ -butyl-7-fluoroquinolin-4-amine

**IV** –  $N^4$ -(7-chloroquinolin-4-yl)- $N^1,N^1$ -diethylpentane-1,4-diamine

**V** –  $N^4$ -(6-methoxyquinolin-8-yl)pentane-1,4-diamine

roquinolin-4-yl)-*N*<sup>1</sup>,*N*<sup>1</sup>-diethylpentane-1,4-diamine (**IV**) and *N*<sup>4</sup>-(6-methoxyquinolin-8-yl)pentane-1,4-diamine (primaquine, PQ, V) (Fig. 1) have been examined as cytotoxic agents against the MCF-7 breast cancer cell line. Some of these compounds were very effective (17). It has been reported that CQ and its analogs have a unique property of being accumulated in the lysosomes, raising intralysosomal pH, and resulting in enhancement of cell killing by cancer therapeutic agents in a variety of different tumors (18). It is well known that many 2-pyridone derivatives revealed diverse biological activities such as anticancer (19), cardiotoxic (20), and potential HIV-1 specific reverse transcriptase inhibiting (21). In view of the above mentioned findings and as a part of our research efforts to explore novel anticancer heterocyclic compounds (22–28), we have synthesized a new series of quinoline derivatives carrying a number of biologically active moieties as analogues to compounds I–V (Fig. 1).

## EXPERIMENTAL

Melting points were uncorrected and determined in an open capillary on a Gallen Kamp melting point apparatus (Sanyo Gallen Kamp, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60 F254, Merck, Germany) were used for thin layer chromatography. A developing solvent system of chloroform/methanol (8:2) was used and the spots were detected by UV light. IR spectra (KBr disc) were recorded using an FT-IR spectrophotometer (Perkin Elmer, USA). <sup>1</sup>H NMR spectra were scanned on a NMR spectrophotometer (Bruker AXS Inc., Switzerland) operating at 500 MHz for <sup>1</sup>H- and 125.76 MHz for <sup>13</sup>C. Chemical shifts are expressed in  $\delta$ -values (ppm) relative to TMS as an internal standard, using DMSO-*d*<sub>6</sub> as a solvent. Elemental analyses were done on a model 2400 CHNSO analyzer (Perkin Elmer, USA). All the values were within  $\pm 0.4$  % of the theoretical values. All reagents used were of analytical grade. The starting material 3-aminoquinoline was purchased from Sigma (USA) and was directly used for the preparation of target compounds.

### Syntheses

2-Cyano-N-(quinolin-3-yl)acetamide (**1**). – A mixture of quinolin-3-amine (1.44 g, 0.01 mol) and ethyl cyanoacetate (1.13 g, 0.01 mol) was fused at 220 °C for 2 h. The reaction mixture was cooled and the obtained product was crystallized from ethanol to give **1**.

4,6-Dimethyl-2-oxo-1-(quinolin-3-yl)-1,2-dihydropyridine-3-carbonitrile (**4**). – A mixture of compound **1** (2.1 g, 0.01 mol) and acetylacetone (5 mL) containing piperidine (0.5 mL) was fused for 6 h. The reaction mixture was cooled and the obtained solid was recrystallized from dioxane to give **4**.

3-Amino-6-methyl-5-(quinolin-3-yl)thieno[3,4-*c*]pyridine-4(5H)-one (**5**). – A mixture of **4** (2.75 g, 0.01 mol) and elemental sulfur (0.32 g, 0.01 mol) in absolute ethanol (30 mL) containing 3 drops of triethylamine was refluxed for 8 h. The obtained solid was crystallized from dioxane to give **5**.

8-Amino-3-methyl-1-oxo-6-phenyl-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**6**), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-*p*-tolyl-1,2-dihydroisoquinoline-7-carbonitrile (**7**), 8-amino-6-(4-hydroxyphenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**8**), 8-amino-6-(4-methoxyphenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-car-

bonitrile (**9**), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-stryl-1,2-dihydroisoquinoline-7-carbonitrile (**10**), 8-amino-6-(2-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**11**), 8-amino-6-(4-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**12**), 8-amino-6-(4-(dimethylamino)phenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**13**), 8-amino-6-(benzo[d][1,3]dioxol-5-yl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**14**), 8-amino-3-methyl-6-(3-nitrophenyl)-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**15**), 8-amino-3-methyl-6-(4-nitrophenyl)-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**16**), 8-amino-6-(2,4-dichlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**17**), 8-amino-6-(2-methoxynaphthalen-1-yl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**18**), 8-amino-6-(4-methoxynaphthalen-1-yl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**19**), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-(thiophen-2-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**20**). *General procedure.* – A mixture of **4** (2.75 g, 0.01 mol) and the respective benzyldenemalononitrile (0.01 mol) in ethanol (20 mL) containing a catalytic amount of piperidine (0.5 mL) was refluxed for 6 h. The obtained solid was filtered and crystallized from dioxane to give **6–20**, respectively (Scheme 1, Table I).

2-Cyano-3-(dimethylamino)-N-(quinolin-3-yl)acrylamide (**21**). – Dimethylformamide-dimethylacetal (1.19 g, 0.01 mol) was added to a solution of **1** (2.11g, 0.01 mol) in dry xylene (20 mL). The reaction mixture was refluxed for 8 h, cooled and the obtained solid was recrystallized from ethanol to give **21**.

2-(4-Oxothiazolidin-2-ylidene)-N-(quinolin-3-yl) acetamide (**22**). – A mixture of **1** (2.11 g, 0.01 mol) and 2-sulfanylacetic acid (0.92 g, 0.01 mol) in dry pyridine (10 mL) was refluxed for 18 h. The reaction mixture was cooled and poured into ice/water. The obtained solid was recrystallized from acetic acid to give **22**.

4-Amino-3-phenyl-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**23**), 4-amino-N-(quinolin-3-yl)-2-thioxo-3-p-tolyl-2,3-dihydrothiazole-5-carboxamide (**24**), 4-amino-3-(4-fluorophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**25**), 4-amino-3-(4-methoxyphenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**26**), 4-amino-3-(4-nitrophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**27**), 4-amino-3-(4-bromophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**28**), 4-amino-3-(4-iodophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**29**). *General procedure.* – To a suspension of **1** (2.11 g, 0.01 mol) in absolute ethanol (20 mL), finely divided sulfur (0.32 g, 0.01 mol), 3 drops of triethylamine, aryl isothiocyanate (0.01 mol) and DMF (10 mL) were added. The reaction mixture was stirred at 60 °C for 6 h, then left to cool at room temperature. The separated product was filtered, washed with ethanol, dried and crystallized from DMF/ethanol (2:1) to give **23–29**, respectively.

2-Amino-N-(quinolin-3-yl)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide (**33**), 2-amino-N-(quinolin-3-yl)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide (**34**), 2-amino-N-(quinolin-3-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (**35**). *General procedure.* – To a solution of **1** (2.11 g, 0.01 mol) in absolute ethanol (30 mL), morpholine (1 mL), cyclopentanone or cyclohexanone and/or cycloheptanone (0.01 mol) and sulfur (0.32 g, 0.01 mol) were added. The reaction mixture was refluxed for 8 h. The separated product was filtered, dried and crystallized from dioxane to give **33–35**, respectively.

Table I. Physical and analytical data of the newly synthesized compounds

Compd. No.	Formula (M <sub>r</sub> )	M. p. (°C)	Yield (%)	Analysis (calcd./found) (%)		
				C	H	N
1	C <sub>12</sub> H <sub>9</sub> N <sub>3</sub> O (211.22)	220.4	92	68.24/68.51	4.29/4.08	19.89/19.59
4	C <sub>17</sub> H <sub>13</sub> N <sub>3</sub> O (275.30)	278.7	86	74.17/74.46	4.76/4.44	15.26/15.51
5	C <sub>17</sub> H <sub>13</sub> N <sub>3</sub> OS (307.37)	199.9	68	66.43/66.64	4.26/4.51	13.67/13.39
6	C <sub>26</sub> H <sub>18</sub> N <sub>4</sub> O (402.45)	147.2	81	77.59/77.27	4.51/4.19	13.92/13.65
7	C <sub>27</sub> H <sub>20</sub> N <sub>4</sub> O (416.47)	97.7	77	77.87/77.56	4.84/4.59	13.45/13.24
8	C <sub>26</sub> H <sub>18</sub> N <sub>4</sub> O <sub>2</sub> (418.45)	269.9	83	74.63/74.31	4.34/4.12	13.39/13.11
9	C <sub>27</sub> H <sub>20</sub> N <sub>4</sub> O <sub>2</sub> (432.47)	119.8	79	74.98/74.63	4.66/4.29	12.95/13.18
10	C <sub>28</sub> H <sub>20</sub> N <sub>4</sub> O (428.48)	245.2	68	78.49/78.27	4.70/4.43	13.08/13.36
11	C <sub>26</sub> H <sub>17</sub> N <sub>4</sub> O (436.89)	156.7	78	71.48/71.26	3.92/3.65	12.82/12.49
12	C <sub>26</sub> H <sub>17</sub> ClN <sub>4</sub> O (436.89)	288.8	68	71.48/71.16	3.92/3.63	12.82/13.11
13	C <sub>28</sub> H <sub>23</sub> N <sub>5</sub> O (445.52)	281.8	63	75.49/75.20	5.20/5.01	15.72/15.38
14	C <sub>27</sub> H <sub>18</sub> N <sub>4</sub> O <sub>3</sub> (446.46)	318.0	74	72.64/72.33	4.06/4.27	12.55/12.29
15	C <sub>26</sub> H <sub>17</sub> N <sub>5</sub> O <sub>3</sub> (447.44)	150.8	67	69.79/69.52	3.83/3.48	15.65/15.41
16	C <sub>26</sub> H <sub>17</sub> N <sub>5</sub> O <sub>3</sub> (447.44)	234.0	77	69.79/69.43	3.83/3.50	15.65/15.34
17	C <sub>26</sub> H <sub>16</sub> Cl <sub>2</sub> N <sub>4</sub> O (471.34)	174.2	78	69.25/69.59	3.42/3.12	11.89/12.24
18	C <sub>31</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub> (482.53)	215.9	59	77.16/77.52	4.60/4.33	11.61/11.30
19	C <sub>31</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub> (482.53)	344.9	63	77.16/77.46	4.60/4.91	11.61/11.35
20	C <sub>24</sub> H <sub>16</sub> N <sub>5</sub> OS (408.48)	128.9	74	70.57/70.88	3.95/3.76	13.72/13.42
21	C <sub>15</sub> H <sub>14</sub> N <sub>4</sub> O (266.30)	187.9	85	67.65/67.36	5.30/5.10	21.04/21.31
22	C <sub>16</sub> H <sub>11</sub> N <sub>3</sub> O <sub>2</sub> S (285.32)	296.6	78	58.93/58.66	3.89/3.60	14.73/14.39
23	C <sub>19</sub> H <sub>14</sub> N <sub>4</sub> OS <sub>2</sub> (378.47)	97.0	88	60.30/60.06	3.73/3.48	14.80/14.52
24	C <sub>20</sub> H <sub>16</sub> N <sub>4</sub> OS <sub>2</sub> (392.50)	112.3	85	61.20/61.49	4.11/4.41	14.27/14.53
25	C <sub>19</sub> H <sub>13</sub> FN <sub>4</sub> OS <sub>2</sub> (396.46)	263.1	71	57.56/57.32	3.31/3.07	14.13/14.40
26	C <sub>20</sub> H <sub>16</sub> N <sub>4</sub> O <sub>2</sub> S <sub>2</sub> (408.50)	275.4	78	58.80/58.54	3.95/3.63	13.72/13.45
27	C <sub>19</sub> H <sub>13</sub> N <sub>3</sub> O <sub>3</sub> S <sub>2</sub> (423.47)	169.9	70	53.89/53.55	3.09/3.37	16.45/16.16
28	C <sub>19</sub> H <sub>13</sub> BrN <sub>4</sub> OS <sub>2</sub> (457.37)	148.6	80	49.90/49.61	2.86/2.48	12.25/12.01
29	C <sub>19</sub> H <sub>13</sub> IN <sub>4</sub> OS <sub>2</sub> (504.37)	138.7	79	45.25/45.51	2.60/2.32	11.11/11.40
33	C <sub>17</sub> H <sub>15</sub> N <sub>3</sub> OS (309.39)	230.0	66	66.00/66.29	4.89/4.57	13.58/13.88
34	C <sub>18</sub> H <sub>17</sub> N <sub>3</sub> OS (323.41)	197.3	69	66.85/66.49	5.30/5.04	12.99/12.66
35	C <sub>19</sub> H <sub>19</sub> N <sub>3</sub> OS (337.44)	161.1	61	67.63/67.37	5.68/5.35	12.45/12.19

Physicochemical and spectral data are given in Tables I and II and synthetic pathways in Schemes 1 and 2.

Table II. Spectral data for compounds

Compd.	IR ( $\nu_{\max}$ , $\text{cm}^{-1}$ )	$^1\text{H}$ NMR (DMSO- $d_6$ ) $^{13}\text{C}$ NMR (DMSO- $d_6$ ) ( $\delta$ , ppm)	Mass ( $m/z$ , %)
1	3260 (NH), 3091 (CH arom.), 2957, 2927 (CH aliph.), 2201 (C≡N), 1700 (C=O), 1617 (C=N)	4.0 (s, 2H, CH <sub>2</sub> ), 7.5, 8.6 (2s, 2H, 2CH quinoline), 7.6–7.9 (m, 4H, Ar-H), 10.8 (s, 1H, NH, D <sub>2</sub> O-exchangeable) 24.7, 115.6, 122.6, 123.8, 125.4, 126.3, 127.7, 128.5, 132.0, 144.1, 144.4, 161.9	211 [M <sup>+</sup> ] (9.4), 68 (100)
4	3062 (CH arom.), 2937, 2870 (CH aliph.), 2218 (C≡N), 1658 (C=O), 1585 (C=N)	2.0 (s, 6H, 2CH <sub>3</sub> ), 6.5 (s, 1H, CH pyridone), 7.3, 8.8 (2s, 2H, 2CH quinoline), 7.5–8.1 (m, 4H, Ar-H) 20.7, 21.7, 100.0, 109.3, 115.6, 127.3, 127.5, 128.4, 128.8, 130.7, 130.8, 135.1, 147.0, 149.5, 152.1, 160.2, 160.8	275 [M <sup>+</sup> ] (13.6), 93 (100)
5	3406, 3326 (NH <sub>2</sub> ), 2976, 2836 (CH aliph.), 1657 (C=O), 1611 (C=N)	1.6 (s, 1H, CH <sub>3</sub> ), 5.1 (s, 1H, CH pyridone), 6.6 (s, 1H, CH thiophene), 7.1, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.3 (m, 6H, Ar-H + NH <sub>2</sub> ) 21.7, 105.4, 123.6, 124.1, 126.2 (2), 127.1 (2), 128.6, 131.8, 134.7, 136.0, 138.2, 141.0, 142.5, 151.2, 161.2	307 [M <sup>+</sup> ] (11.5), 58 (100)
6	3405, 3386 (NH <sub>2</sub> ), 3066 (CH arom.), 2910, 2861 (CH aliph.), 2184 (C≡N), 1695 (C=O), 1586 (C=N)	1.7 (s, 3H, CH <sub>3</sub> ), 5.2 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.4 (s, 1H, CH pyridone), 7.1, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.3 (m, 10H, Ar-H) 21.6, 95.2, 101.8, 114.2, 116.7, 116.9, 122.8, 123.6, 124.7, 127.5, 127.9, 128.6 (2), 128.9, 129.1, 129.2 (2), 129.4, 135.1 (2), 138.4, 139.3, 142.6, 144.8, 148.1, 157.4	402 [M <sup>+</sup> ] (27.1), 127 (100)
7	3310, 3205 (NH <sub>2</sub> ), 3100 (CH arom.), 2920, 2863 (CH aliph.), 2184 (C≡N), 1689 (C=O), 1599 (C=N)	1.3 (s, 3H, CH <sub>3</sub> ), 2.3 (s, 3H, CH <sub>3</sub> tolyl), 6.0 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.0, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.4 (m, 9H, Ar-H) 18.4, 24.0, 97.4, 100.4, 116.6, 116.8, 117.9, 125.2 (2), 127.4, 127.9, 129.1 (2), 128.5, 128.8, 129.3 (2), 129.7, 132.3, 135.8, 137.3, 138.3, 139.7, 145.2 (2), 149.7, 158.3	416 [M <sup>+</sup> ] (24.7), 77 (100)
8	3431 (br, OH), 3371, 3312 (NH <sub>2</sub> ), 3069 (CH arom.), 2927, 2863 (CH aliph.), 2217 (C≡N), 1661 (C=O), 1585 (C=N)	2.0 (s, 3H, CH <sub>3</sub> ), 6.0 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.0, 8.8 (2s, 2H, 2CH quinoline), 7.7–8.5 (m, 9H, Ar-H), 9.0 (s, 1H, OH, D <sub>2</sub> O-exchangeable) 20.7, 92.4, 100.0, 115.6, 116.8 (2), 118.1, 118.3, 123.7, 126.1, 127.3, 127.5 (2), 128.4 (2), 128.8 (2), 130.7, 135.1 (2), 139.6, 147.0 (2), 149.5, 152.1, 160.2	418 [M <sup>+</sup> ] (39.9), 163 (100)
9	3378, 3296 (NH <sub>2</sub> ), 3061 (CH arom.), 2971, 2819 (CH aliph.), 2191 (C≡N), 1676 (C=O), 1599 (C=N)	1.6 (s, 3H, CH <sub>3</sub> ), 3.8 (s, 3H, OCH <sub>3</sub> ), 6.2 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.3 (s, 1H, CH pyridone), 6.9, 6.8 (2s, 2H, 2CH quinoline), 7.1–8.4 (m, 9H, Ar-H) 18.4, 56.0, 96.5, 99.9, 113.7 (2), 114.4, 115.1, 116.0, 125.2, 127.3, 127.5, 127.7, 128.1, 128.4, 128.8 (2), 129.6, 130.0, 135.6, 138.0, 140.2, 146.9 (2), 149.9, 153.9, 160.5	432 [M <sup>+</sup> ] (45.9), 56 (100)
10	3391, 3286 (NH <sub>2</sub> ), 3100 (CH arom.), 2976, 2912 (CH aliph.), 2218 (C≡N), 1663 (C=O), 1609 (C=N)	1.5 (s, 3H, CH <sub>3</sub> ), 6.2 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.4 (s, 1H, CH pyridone), 6.8, 7.3 (2d, 2H, CH=CH, $J = 7.4$ Hz), 7.4, 8.8 (2s, 2H, 2CH quinoline), 7.5–8.5 (m, 10H, Ar-H) 20.7, 97.6, 100.0, 109.3, 115.6 (2), 123.6, 123.8, 124.1, 124.4, 125.0, 126.8, 127.1 (2), 127.6 (2), 128.3 (2), 128.9 (2), 135.1 (2), 143.2 (2), 147.0 (2), 149.5, 152.1	428 [M <sup>+</sup> ] (44.7), 93 (100)

<p><b>11</b> 3398, 3334 (NH<sub>2</sub>), 3077 (CH arom.), 2929, 2845 (CH aliph.), 2219 (C≡N), 1653 (C=O), 1576 (C=N), 754 (C-Cl)</p>	<p>1.5 (s, 3H, CH<sub>3</sub>), 5.9 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O- exchangeable), 6.5 (s, 1H, CH pyridone), 7.2, 8.8 (2s, 2H, 2CH quinoline), 7.4–8.1 (m, 9H, Ar-H) 20.7, 88.1, 100.1, 115.6 (2), 115.9, 126.9 (2), 127.3, 127.5, 127.7, 128.4, 128.8, 129.3, 129.7 (2), 130.0, 131.3, 133.2, 135.1 (2), 142.3, 147.0, 149.5, 152.1, 160.2</p>	<p>437 [M<sup>+</sup>] (19.8), 76 (100)</p>
<p><b>12</b> 3265, 3212 (NH<sub>2</sub>), 3091 (CH arom.), 2976, 2844 (CH aliph.), 2218 (C≡N), 1658 (C=O), 1587 (C=N), 818 (C-Cl)</p>	<p>1.6 (s, 3H, CH<sub>3</sub>), 4.4 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.0, 8.8 (2s, 2H, 2CH quinoline), 7.2–8.3 (m, 9H, Ar-H) 22.1, 85.2, 101.6, 115.8, 116.0 (2), 122.7, 123.4, 124.8, 126.1, 128.6, 128.7, 129.8 (2), 130.3 (2), 131.6, 131.9, 134.3 (2), 136.1, 142.7, 143.6, 149.1 (2), 157.8</p>	<p>436 [M<sup>+</sup>] (1.8), 227 (100)</p>
<p><b>13</b> 3406, 3399 (NH<sub>2</sub>), 3047 (CH arom.), 2221 (C≡N), 1654 (C=O), 1592 (C=N)</p>	<p>2.0 (s, 3H, CH<sub>3</sub>), 2.9 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>), 6.0 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O-exchangeable), 6.1 (s, 1H, CH pyridone), 7.0, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.2 (m, 9H, Ar-H) 21.9, 40.1 (2), 95.5, 102.6, 111.7 (2), 112.0, 115.4, 116.0, 122.2, 127.3 (2), 127.4 (2), 128.4, 128.8 (2), 129.8, 130.7, 135.2, 141.3 (2), 146.9 (2), 149.8, 150.5, 154.8</p>	<p>446 [M<sup>+</sup>] (13.9), 91 (100)</p>
<p><b>14</b> 3368, 3276 (NH<sub>2</sub>), 3050 (CH arom.), 2921, 2898 (CH aliph.), 2215 (C≡N), 1659 (C=O), 1597 (C=N)</p>	<p>2.0 (s, 3H, CH<sub>3</sub>), 6.0 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O-exchangeable), 6.1 (s, 1H, CH pyridone), 6.5 (s, 2H, O-CH<sub>2</sub>-O), 7.0, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.2 (m, 8H, Ar-H) 20.7, 94.3, 100.8, 101.6, 109.3, 116.8 (2), 118.3, 118.7, 121.9, 122.4, 124.6, 127.3, 127.5, 128.4, 128.8, 130.7 (2), 135.1 (2), 142.0, 147.0, 149.0 (2), 152.1 (2), 157.2</p>	<p>446 [M<sup>+</sup>] (6.9), 109 (100)</p>
<p><b>15</b> 3431, 3291 (NH<sub>2</sub>), 3100 (CH arom.), 2946, 2908 (CH aliph.), 2200 (C≡N), 1653 (C=O), 1595 (C=N), 1568, 1361 (NO<sub>2</sub>)</p>	<p>1.6 (s, 3H, CH<sub>3</sub>), 5.8 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.5, 8.8 (2s, 2H, 2CH quinoline), 7.6–8.2 (m, 8H, Ar-H) 20.7, 95.7, 100.0, 109.3, 115.6 (2), 122.1, 123.3 (2), 127.3 (2), 127.5, 128.4, 128.7, 130.4, 130.7, 130.8, 135.1 (2), 140.8 (2), 142.6, 147.0, 149.5 (2), 160.2</p>	<p>447 [M<sup>+</sup>] (15.6), 68 (100)</p>
<p><b>16</b> 3386, 3351 (NH<sub>2</sub>), 3081 (CH arom.), 2917, 2866 (CH aliph.), 2189 (C≡N), 1654 (C=O), 1585 (C=N), 1518, 1343 (NO<sub>2</sub>)</p>	<p>1.6 (s, 3H, CH<sub>3</sub>), 6.0 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.2, 8.8 (2s, 2H, 2CH quinoline), 7.4–8.5 (m, 9H, Ar-H) 18.5, 94.6, 100.0, 109.3, 115.6 (2), 123.6 (2), 124.2 (2), 127.3, 127.5, 128.4, 128.7 (2), 130.1, 130.4, 135.1 (2), 142.6, 144.8 (2), 147.0 (2), 149.5, 152.1</p>	<p>447 [M<sup>+</sup>] (28.3), 74 (100)</p>
<p><b>17</b> 3391, 3317 (NH<sub>2</sub>), 3100 (CH arom.), 2929, 2810 (CH aliph.), 2216 (C≡N), 1660 (C=O), 1585 (C=N), 751 (C-Cl)</p>	<p>1.5 (s, 3H, CH<sub>3</sub>), 6.0 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O-exchangeable), 6.9 (s, 1H, CH pyridone), 7.3, 8.8 (2s, 2H, 2CH quinoline), 7.4–8.5 (m, 8H, Ar-H) 18.5, 93.6, 100.0, 109.3, 115.6 (2), 127.3 (2), 127.5 (2), 128.1, 128.4, 128.7, 129.4, 130.7, 130.8, 132.2 (2), 135.7 (2), 142.1 (2), 147.0 (2), 149.5, 157.4</p>	<p>471 [M<sup>+</sup>] (17.1), 58 (100)</p>
<p><b>18</b> 3436, 3421 (NH<sub>2</sub>), 3058 (CH arom.), 2934, 2836 (CH aliph.), 2213 (C≡N), 1654 (C=O), 1578 (C=N)</p>	<p>2.0 (s, 3H, CH<sub>3</sub>), 3.8 (s, 3H, OCH<sub>3</sub>), 6.0 (s, 2H, NH<sub>2</sub>, D<sub>2</sub>O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.2, 8.8 (2s, 2H, 2CH quinoline), 7.4–8.4 (m, 11H, Ar-H) 18.5, 56.0, 98.1, 100.0, 113.7, 115.6, 116.1, 122.9, 123.9 (2), 127.1, 127.3, 127.5, 127.6, 128.4 (2), 128.7 (2), 130.5 (2), 130.7 (2), 133.0, 135.6 (2), 142.3, 147.0 (2), 149.5, 156.3, 160.2</p>	<p>483 [M<sup>+</sup>] (68.6), 286 (100)</p>

19	3404, 3395 (NH <sub>2</sub> ), 3100 (CH arom.), 2961, 2846 (CH aliph.), 2214 (C≡N), 1653 (C=O), 1589 (C=N)	1.8 (s, 3H, CH <sub>3</sub> ), 4.0 (s, 3H, OCH <sub>3</sub> ), 6.0 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.0, 8.5 (2s, 2H, 2CH quinoline), 7.2–8.3 (m, 11H, Ar-H)	483 [M <sup>+</sup> ] (26.5), 68 (100)
		20.7, 57.4, 92.1, 100.0, 109.3, 113.2, 115.6, 117.8, 119.9, 122.8, 123.6, 124.4, 124.8, 124.9, 125.0, 126.3, 127.3, 127.5, 128.4, 128.8, 130.7 (2), 130.8, 135.1, 138.5, 139.6 (2), 147.0, 149.5, 152.1 (2)	
20	3401, 3381 (NH <sub>2</sub> ), 3066 (CH arom.), 2972, 2818 (CH aliph.), 2190 (C≡N), 1688 (C=O), 1508 (C=N)	1.8 (s, 3H, CH <sub>3</sub> ), 5.9 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.7 (s, 1H, CH pyridone), 7.0, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.2 (m, 8H, Ar-H)	408 [M <sup>+</sup> ] (11.6), 201 (100)
		18.5, 97.1, 102.8, 109.3, 115.6 (2), 120.1, 127.3 (2), 127.5 (2), 128.4, 128.8, 129.9 (2), 130.7, 130.8, 133.5, 135.1, 140.2 (2), 142.6, 149.6, 153.7	
21	3287 (NH), 3079 (CH arom.), 2936, 2871 (CH aliph.), 2224 (C≡N), 1688 (C=O), 1593 (C=N)	2.6 (s, 6H, 2CH <sub>3</sub> ), 7.0–8.3 (m, 4H, Ar-H), 7.5 (s, 1H, CH), 7.3, 8.6 (2s, 2H, 2CH quinoline), 8.9 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	266 [M <sup>+</sup> ] (56.7), 121 (100)
		40.0 (2), 90.0, 118.8, 125.6 (2), 127.2, 127.5, 128.2, 130.2, 135.5 (2), 146.5, 154.9, 162.3	
22	3159 (NH), 3100 (CH arom.), 2966, 2871 (CH aliph.), 1705, 1679 (2 C=O), 1581 (C=N)	3.7 (s, 2H, CH <sub>2</sub> CO), 5.8 (s, 1H, CH), 7.5, 8.8 (2s, 2H, 2CH quinoline), 7.6–8.0 (m, 4H, Ar-H), 10.3 (s, 1H, NH, D <sub>2</sub> O-exchangeable), 11.6 (s, 1H, NH, thiazolidine, D <sub>2</sub> O-exchangeable)	285 [M <sup>+</sup> ] (13.4), 105 (100)
		32.1, 91.9, 120.7, 126.9, 127.3, 127.5, 128.0, 128.4, 133.5, 143.7, 144.1, 155.6, 165.9, 174.1	
23	3410, 3286 (NH, NH <sub>2</sub> ), 3066 (CH arom.), 1686 (C=O), 1577 (C=N), 1234 (C=S)	4.5 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.9, 8.7 (2s, 2H, 2CH quinoline), 7.1–8.2 (m, 9H, Ar-H), 11.0 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	378 [M <sup>+</sup> ] (12.8), 91 (100)
		81.9, 123.1 (2), 124.3, 124.5, 127.4 (2), 127.7, 128.1, 129.0, 129.1 (2), 133.4, 135.5, 138.0, 142.3, 156.9, 162.2, 189.4	
24	3379, 3234 (NH, NH <sub>2</sub> ), 3057 (CH arom.), 2919, 2886 (CH aliph.), 1669 (C=O), 1586 (C=N), 1273 (C=S)	2.3 (s, 3H, CH <sub>3</sub> ), 4.5 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 6.9, 8.6 (2s, 2H, 2CH quinoline), 7.1–8.2 (m, 8H, Ar-H), 10.9 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	392 [M <sup>+</sup> ] (9.6), 127 (100)
		20.8, 81.7, 121.6, 122.9, 127.6, 18 (2), 128.3, 128.5, 128.8, 129.1 (2), 129.5, 133.5 (2), 138.2, 141.6, 153.3, 164.1, 189.6	
25	3367, 3286 (NH, NH <sub>2</sub> ), 3100 (CH arom.), 1667 (C=O), 1589 (C=N), 1224 (C=S)	4.5 (s, 1H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 7.1, 8.6 (2s, 2H, 2CH quinoline), 7.4–8.1 (m, 8H, Ar-H), 9.7 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	396 [M <sup>+</sup> ] (14.1), 119 (100)
		82.0, 117.0 (2), 123.7, 126.9, 127.5, 127.7, 127.9 (2), 128.4, 131.4, 131.5, 132.7, 144.0, 145.7, 152.9, 160.9, 164.8, 185.9	
26	3415, 3339 (NH, NH <sub>2</sub> ), 3071 (CH arom.), 2961, 2831 (CH aliph.), 1683 (C=O), 1586 (C=N), 1234 (C=S)	3.8 (s, 3H, OCH <sub>3</sub> ), 4.5 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 7.1, 8.6 (2s, 2H, 2CH quinoline), 7.3–8.0 (m, 8H, Ar-H), 9.7 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	408 [M <sup>+</sup> ] (8.7), 93 (100)
		55.4, 81.9, 115.3 (2), 123.5, 126.9, 127.2, 127.5, 127.7, 127.8 (2), 128.5, 130.1, 132.7, 144.1, 145.7, 153.0, 160.2, 160.9, 186.1	
27	3286, 3212 (NH, NH <sub>2</sub> ), 3068 (CH arom.), 1658 (C=O), 1591 (C=N), 1202 (C=S)	4.5 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 7.0, 8.6 (2s, 2H, 2CH quinoline), 7.4–8.2 (m, 8H, Ar-H), 11.6 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	423 [M <sup>+</sup> ] (44.9), 102 (100)
		86.3, 121.0 (2), 122.8, 123.5, 124.5, 127.3, 128.7 (2), 130.5 (2), 135.6, 139.1, 139.6, 142.8, 144.0, 157.2, 165.7, 187.6	



28	3310, 3286 (NH, NH <sub>2</sub> ), 3100 (CH arom.), 1691 (C=O), 1589 (C=N), 1261 (C=S)	4.5 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 7.0, 8.5 (2s, 2H, 2CH quinoline), 7.2–8.2 (m, 8H, Ar-H), 11.1 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	457 [M <sup>+</sup> ] (3.1), 139 (100)
		91.2, 118.6, 123.5, 124.5, 125.5, 127.2, 128.2, 128.4 (2), 130.4, 130.5 (2), 131.4, 137.0, 139.8, 145.1, 156.1, 166.9, 189.6	
29	3229, 3186 (NH, NH <sub>2</sub> ), 3081 (CH arom.), 1686 (C=O), 1587 (C=N), 1247 (C=S)	4.5 (s, 2H, NH <sub>2</sub> , D <sub>2</sub> O-exchangeable), 7.0, 8.5 (2s, 2H, 2CH quinoline), 7.1–8.2 (m, 8H, Ar-H), 11.1 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	504 [M <sup>+</sup> ] (42.4), 234 (100)
		88.7, 95.2, 125.7, 127.2, 127.5, 128.2, 128.6 (2), 128.6, 130.8, 135.1, 136.3, 137.0 (2), 138.0, 147.6, 155.1, 162.9, 189.0	
33	3406, 3381 (NH, NH <sub>2</sub> ), 3051 (CH arom.), 2936, 2847 (CH aliph.), 1680 (C=O), 1590 (C=N)	2.3–3.0 (m, 6H, 3CH <sub>2</sub> cyclo), 7.1, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.4 (m, 6H, Ar-H + NH <sub>2</sub> ), 11.8 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	309 [M <sup>+</sup> ] (78.4), 76 (100)
		22.6, 28.8, 37.7, 116.6, 125.1, 125.5 (2), 125.9, 126.4, 127.9, 128.3, 135.1, 140.8, 141.6, 144.5, 165.0, 165.9	
34	3247, 3176 (NH, NH <sub>2</sub> ), 3091 (CH arom.), 2926, 2853 (CH aliph.), 1657 (C=O), 1610 (C=N)	1.3–2.7 (m, 8H, 4CH <sub>2</sub> cyclo), 7.2, 8.6 (2s, 2H, 2CH quinoline), 7.7–8.2 (m, 6H, Ar-H + NH <sub>2</sub> ), 10.5 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	323 [M <sup>+</sup> ] (18.3), 72 (100)
		22.0, 22.9, 24.0, 25.3, 110.2, 120.0, 126.7 (2), 127.7, 128.1, 128.5, 129.6, 132.2, 136.8 (2), 146.2, 161.2, 167.1	
35	3420, 3381 (NH, NH <sub>2</sub> ), 3100 (CH arom.), 2927, 2861 (CH aliph.), 1676 (C=O), 1599 (C=N)	1.2–2.6 (m, 10H, 5CH <sub>2</sub> cyclo), 7.0, 8.6 (2s, 2H, 2CH quinoline), 7.4–7.9 (m, 6H, Ar-H + NH <sub>2</sub> ), 10.7 (s, 1H, NH, D <sub>2</sub> O-exchangeable)	337 [M <sup>+</sup> ] (86.1), 94 (100)
		22.6, 27.4, 30.2, 30.8, 31.4, 116.5, 122.6, 124.1 (2), 125.7, 126.8, 127.1, 128.8, 135.6, 137.2, 138.0, 142.2, 161.6, 163.8	

### In vitro antitumor activity

The cytotoxic activity *in vitro* of the newly synthesized compounds was evaluated using the sulforhodamine B stain (SRB) assay and the method of Skehan (29). The human breast cancer cell line (obtained from the National Cancer Institute, Cairo, Egypt) was maintained at 37 °C in 5 % CO<sub>2</sub> as sub-confluent monolayers in 80 cm<sup>3</sup> culture flasks (Nunc, Sigma, USA) and was subcultured once or twice weekly in Dulbecco's modification of Eagle's medium (Flow, Sigma, USA) supplemented with 5 % heat-inactivated fetal calf serum (FCS) and 1 mmol L<sup>-1</sup> L-glutamine (Sigma). During the experiments, 50 µg mL<sup>-1</sup> gentamicin (Sigma) was added to the culture medium. Passage levels were in the range of 5–20 according to the original receipt. Cells were harvested from exponential phase cultures by trypsinisation, counted and plated in 96-well flat bottomed microliter plates (Greiner Labortechnik, Germany) (100 µL cell suspension containing 10<sup>4</sup> cells per well). Following plating and a 24-h recovery to allow cells to resume exponential growth, 100 µL culture medium or culture medium containing the drug were added to the wells. Test compounds were dissolved in DMSO as a 0.1 µmol L<sup>-1</sup> stock solution (the final concentration of DMSO in culture medium was less than 0.1 %). Different concentrations of each test compound (5, 12, 25 and 50 µmol L<sup>-1</sup>) were obtained by dilution with phosphate buffered saline (PBS) then added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C and

in an atmosphere of 5 % CO<sub>2</sub>. Forty-eight hours after drug addition, cells were fixed with 50 % trichloroacetic acid at 4 °C (50 µL per well) for 1 h, washed with 1 % acetic acid and stained for 30 min with 50 µL of 0.4 % (*m/V*) sulphorhodamine (SRB) dissolved in 1 % ace-

Table III. In vitro cytotoxic activity of the newly synthesized compounds 1, 4–29, 33–35 against the human breast cancer cell line (MCF7)

Compound No.	IC <sub>50</sub> (µg mL <sup>-1</sup> )	IC <sub>50</sub> (µmol L <sup>-1</sup> )
1	22.7	107.5
4	39.7	144.3
5	19.1	62.2
6	15.7	39.0
7	15.4	37.0
8	18.7	44.7
9	24.4	56.4
10	33.1	77.3
11	18.5	42.3
12	22.6	51.8
13	NA	NA
14	NA	NA
15	23.9	53.4
16	NA	NA
17	NA	NA
18	43.7	90.4
19	NA	NA
20	40.1	98.2
21	10.7	40.2
22	NA	NA
23	NA	NA
24	22.4	57.1
25	11.8	29.7
26	NA	NA
27	11.3	26.7
28	24.4	53.3
29	NA	NA
33	20.5	66.3
34	10.7	33.1
35	12.7	37.6
Doxorubicin	26.3	47.9

NA – no activity observed under experimental conditions.

tic acid. Excess unbound dye was removed by four washes with 1 % acetic acid and the attached stain was recovered with Tris-EDTA buffer. Colour intensity was measured using an enzyme-linked immunosorbent assay ELISA reader (BMG LABTECH GmbH, Germany). Absorbance was measured at 510 nm. The relation between the surviving fraction and drug concentration was plotted to get the survival curve for the breast cancer cell line (MCF7) after specified time (29). The molar concentration required for 5 % inhibition of cell viability ( $IC_{50}$ ) was preliminarily calculated from the constructed dose-response curve using the Prism software (Graphpad, Inc., La Jolla, USA) and the results are presented in Table III.

## RESULTS AND DISCUSSION

### Chemistry

Schemes 1 and 2 outline the synthetic pathways used to obtain compounds 1–35. The solvent-free reaction of aryl amines with ethyl cyanoacetate is well known as one of the most widely used synthetic methods. Thermal fusion of 3-aminoquinoline with ethyl cyanoacetate at 220 °C afforded the corresponding 2-cyano-*N*-(quinolin-*N*-3-yl)acetamide (1). The structure of novel compounds was established on the basis of elemental analysis and spectral data. IR spectrum of compound 1 showed bands at 3260  $\text{cm}^{-1}$  NH, and 2201  $\text{cm}^{-1}$  C≡N, while  $^1\text{H-NMR}$  spectrum revealed a singlet at 4.0 ppm assigned to the  $\text{CH}_2$  group. In addition, the structure of compound 1 was confirmed through X-ray crystallography (30) (Figs. 2 and 3).

The present study was aimed to prepare novel quinolone derivatives using cyanoacetamide 1 as strategic starting material. Thus, interaction of compound 1 with acetylacetone furnished the corresponding 4,6-dimethyl-2-oxo-1-(quinolin-3-yl)-1,2-dihydropyridine-3-carbonitrile 4. It can be postulated that the reaction initially proceeded *via* a nucleophilic attack to form Michael adduct 2 which in turn cyclized to product 3. Elimination of two molecules of water gave 1,2-dihydropyridine 4. IR spectrum of 4 showed the absence of  $\text{NH}_2$  group and the presence of bands at 2937 and 2870  $\text{cm}^{-1}$  (CH aliphatic), 2218  $\text{cm}^{-1}$  (C≡N), and 1658  $\text{cm}^{-1}$  (C=O). Its  $^1\text{H NMR}$  spectrum displayed the following signals: 2.0 ppm for  $2\text{CH}_3$  and 6.5 ppm for pyridinone CH. Interaction of 4 with elemental sulfur in ethanolic triethylamine furnished the corresponding thienopyridine derivative 5. Its IR spectrum revealed characteristic bands at 3406, 3326 ( $\text{NH}_2$ ), 1657  $\text{cm}^{-1}$  (C=O), and 1611  $\text{cm}^{-1}$  (C=N).  $^1\text{H}$




Fig. 2. Oak Ridge thermal ellipsoid plot (ORTEP) diagram of the title compound 1 drawn at 40 % ellipsoids for non-hydrogen atoms.





Fig. 3. Crystal packing of compound **1** showing intermolecular hydrogen bonds as dashed lines.


NMR spectrum showed signals at 1.6 ppm for  $\text{CH}_3$ , 5.1 ppm for pyridinone CH, and 6.6 ppm for thiophene CH.  $^{13}\text{C}$  NMR spectrum revealed a singlet at 161.2 ppm assigned to  $\text{C}=\text{O}$ . Application of Michael addition of **4** to benzylidene malononitriles in absolute ethanol in the presence of piperidine yielded the corresponding 1,2-dihydroisoquinoline derivatives **6–20**, *via* loss of the  $\text{HCN}$  molecule (Scheme 1). IR spectra of compounds **6–20** revealed the presence of bands for  $\text{NH}_2$ ,  $\text{C}\equiv\text{N}$ ,  $\text{C}=\text{O}$  and  $\text{C}=\text{N}$ .  $^1\text{H}$  NMR spectra of compounds **6–20** exhibited a singlet at 6.2–4.4 ppm assigned to the  $\text{NH}_2$  group. Treatment of **1** with dimethylformamide-dimethylacetal (DMF-DMA) in dry xylene gave the corresponding enamine derivative **21**. IR spectrum showed bands at  $3287\text{ cm}^{-1}$  ( $\text{NH}$ ),  $2224\text{ cm}^{-1}$  ( $\text{C}\equiv\text{N}$ ), and  $1688\text{ cm}^{-1}$  ( $\text{C}=\text{O}$ ).  $^1\text{H}$  NMR spectrum revealed signals at 2.6 ppm for  $\text{N}(\text{CH}_3)$ , 7.5 ppm for the CH group and 8.9 ppm for the NH group. Interaction of compound **1** with 2-sulfanylacetic acid in pyridine produced the corresponding thiazolidine derivative **22**. Compound **22** was characterized by the presence of a strong absorption band at  $1705\text{ cm}^{-1}$  in the IR spectrum specific for the thiazolidinone as a proof of cyclization. In the  $^1\text{H}$  NMR spectrum, it was the presence of a singlet equivalent to two protons at 3.7 ppm, representing the C-5 protons of the thiazolidinone nucleus. The  $^{13}\text{C}$  NMR spectrum of compound **22** showed signals at 174.1 and 32.1 ppm (C-4 and C-5 in the thiazolidinone nucleus). On the other hand, 4-amino-3-substituted-*N*-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazide-5-carboxamides **23–29** were obtained by the reaction of **1** with sulfur and aryl isothiocyanate in DMF-EtOH containing triethylamine as a catalyst. IR spectra of compounds **23–29** showed bands for the  $\text{NH}$ ,  $\text{NH}_2$ ,  $\text{C}=\text{O}$ ,  $\text{C}=\text{N}$ ,  $\text{C}=\text{S}$  groups.  $^1\text{H}$  NMR spectra revealed a singlet at 4.5 ppm assigned to the  $\text{NH}_2$

group.  $^{13}\text{C}$  NMR spectra of compounds **23–29** revealed signals at 189.6–183.9 ppm for C=S groups.

Finally, the corresponding thiophene derivatives **33–35** were obtained *via* the reaction of **1** with cyclopentanone or cyclohexanone and/or cycloheptanone and sulfur in a mixture of DMF/EtOH containing a catalytic amount of morpholine. The reaction may be explained *via* the intermediates **30–32** (Scheme 2). Their IR spectra revealed bands at 3420–3176  $\text{cm}^{-1}$  (NH,  $\text{NH}_2$ ) and 1680–1657  $\text{cm}^{-1}$  (C=O).  $^1\text{H}$  NMR spectrum of **33** exhibited signals at 2.3–3.0 ppm for the 3-cyclopentyl  $\text{CH}_2$  group.  $^1\text{H}$  NMR spectrum of **34** showed signals at 1.3–2.7 ppm for the 4-cyclohexyl  $\text{CH}_2$  group.  $^1\text{H}$  NMR spectrum of **35** revealed signals at 1.2–2.6 ppm corresponding to the 5-cycloheptyl  $\text{CH}_2$  group.



Schemes 1



Schemes 2

### In vitro antitumor activity

The  $IC_{50}$  concentrations are presented in Table III. Most of the synthesized compounds showed better cytotoxic activity than doxorubicin ( $IC_{50}$  47.9  $\mu\text{mol L}^{-1}$ ) against the MCF7 cell line except compounds **1**, **4**, **18** and **20** ( $IC_{50}$  values: 98–108  $\mu\text{mol L}^{-1}$ ). The quinoline derivative carrying dihydrothiazole with 4-nitrophenyl and thioxo moiety (**27**), dihydrothiazole with 4-fluorophenyl and thioxo moiety (**25**), tetrahydrobenzothiothiophene (**34**), dihydroisoquinoline with 4-methylphenyl and carbonitrile moiety (**7**), tetrahydro-4-*H*-cycloheptathiophene (**35**), dihydroisoquinoline with unsubstituted phenyl moiety (**6**), acrylamide moiety (**21**), dihydroisoquinoline with 2-chlorophenyl moiety (**11**), dihydroisoquinoline

with 4-hydroxyphenyl moiety (**8**) with exhibited good cytotoxic activity better than doxorubicin as reference drug ( $IC_{50}$  26.7 to 44.7  $\mu\text{mol L}^{-1}$ ). A closer look into the structure activity relationship indicates that addition of dihydrothiazole with thioxo group at 2-position, 4-nitrophenyl at 3-position, free amino group at 4-position, dihydrothiazole with thioxo group at 2-position, 4-fluorophenyl at 3-position, free amino group at 4-position and tetrahydrobenzo[*b*]thiophene with free amino group at 2-position was proven to be successful in the case of compounds **27**, **25** and **34**, which showed an increase in activity. Also, quinolone incorporating tetrahydrobenzo[*b*]thiophene (**34**) with  $IC_{50}$  33.1  $\mu\text{mol L}^{-1}$  exhibited higher activity than cyclopenta[*b*]thiophene (**33**) with  $IC_{50}$  66.3  $\mu\text{mol L}^{-1}$ . The presence of the cyclohepta[*b*]thiophene ring in compound (**35**) ( $IC_{50}$  37.6  $\mu\text{mol L}^{-1}$ ) enhanced the anti-breast cancer activity more than the corresponding cyclopenta[*b*]thiophene (**33**) ( $IC_{50}$  66.3  $\mu\text{mol L}^{-1}$ ). In addition, quinoline bearing dihydroisoquinoline with 4-chlorophenyl (**12**), dihydroisoquinoline with 3-nitrophenyl moiety (**15**) and dihydrothiazole with 4-bromophenyl moiety (**28**) were nearly as active as doxorubicin ( $IC_{50}$  51.8 to 53.4  $\mu\text{mol L}^{-1}$ ). On the other hand, compounds **5**, **9**, **10**, **24** and **33** exhibited moderate activity. Compounds **1**, **4**, **18** and **20** were the least active compounds in this series compared to doxorubicin, while the remaining compounds revealed no activity.

## CONCLUSIONS

The objective of the present study was to synthesize and investigate the anti-breast cancer activity of some novel quinoline derivatives bearing biologically active moieties. All the synthesized compounds were characterized and evaluated for their anti-breast cancer activity and it was found that 4-amino-3-(4-nitrophenyl)-*N*-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**27**), 4-amino-3-(4-fluorophenyl)-*N*-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**25**), 2-amino-*N*-(quinolin-3-yl)-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carboxamide (**34**), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-*p*-tolyl-1,2-dihydroisoquinoline-7-carbonitrile (**7**), 2-amino-*N*-(quinolin-3-yl)-5,6,7,8-tetrahydro-4*H*-cyclohepta[*b*]thiophene-3-carboxamides (**35**), 8-amino-3-methyl-1-oxo-6-phenyl-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**6**), 2-cyano-3-(dimethylamino)-*N*-(quinolin-3-yl)acrylamide (**21**), 8-amino-6-(2-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**11**) and 8-amino-6-(4-hydroxyphenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**8**) exhibited anti-breast cancer activity higher than the positive control doxorubicin. Also, it was found that 8-amino-6-(4-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**12**), 4-amino-3-(4-bromophenyl)-*N*-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (**28**), and 8-amino-3-methyl-6-(3-nitrophenyl)-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (**15**) are almost as active as doxorubicin.

*Acknowledgements.* – The authors extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this research through the Research Group Project No. RGP-VPP- 302.

## REFERENCES

1. H. Frankish, 15 Million new cancer cases per year by 2020, says WHO, *Lancet* **361** (2003) 1278–1287; DOI: 10.1016/S0140-6736(03)13038-3.

2. K. Kubo, T. Shimizu, S. I. Ohyama, H. Murooka, A. Iwai, K. Nakamura, K. Hasegawa, Y. Kobayashi, N. Takahashi, K. Takahashi, S. Kato, T. Izawa and T. Isoe, Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of *N*-phenyl-*N'*-(4-(4-quinolyloxy)phenyl)-ureas, *J. Med. Chem.* **48** (2005) 1359–1366; DOI: 10.1021/jm030427r.
3. R. O'Connor, Mdm-mediated ubiquitylation: P53 and beyond, a review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance, *Curr. Cancer Drug Targets* **9** (2009) 273–280; DOI: 10.2174/156800909788166583.
4. C. Hu, V. R Solomon and G. L. Ulibarri, The efficacy and selectivity of tumor cell killing by AKT inhibitors are substantially increased by chloroquin, *Bioorg. Med. Chem.* **16** (2008) 7888–7893; DOI: 10.1016/j.bmc.2008.07.076.
5. Y. C. Mayur, G. J. Peters, V. V. Prasad, C. Lemo and N. K. Sathish, Design of new drug molecules to be used in reversing multidrug resistance in cancer, *Curr. Cancer Drug Targets* **9** (2009) 298–306; DOI: 10.2174/156800909788166619.
6. M. G. Ferlin, B. Gatto, G. Chiarello and M. Palumbo, Pyrroloquinoline derivatives as potential antineoplastic drugs, *Bioorg. Med. Chem.* **8** (2000) 1415–1422; DOI: 10.1016/S0968-0896(00)00060-2.
7. M. S. Alsaïd, M. S. Bashandy, S. I. Al-Qasoumi and M. M. Ghorab, Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives, *Eur. J. Med. Chem.* **46** (2011) 137–141; DOI: 10.1016/j.ejmech.2010.10.024.
8. S. Pédeboscq, D. Gravier, F. Casadebaig, G. Hou, A. Gissot, F. De Giorgi, F. Ichas, J. Cambar and J. P. Pometan, Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells, *Eur. J. Med. Chem.* **45** (2010) 2473–2479; DOI: 10.1016/j.ejmech.2010.02.032.
9. R. L. Weinkauff, A. Y. Chen, C. Yu, L. Liu, L. Barrows and E. J. LaVoie, Antineoplastic activity of benzimidazo[1,2-*b*] isoquinolines, indolo[2,3-*b*]quinolines, and pyridocarbazoles, *Bioorg. Med. Chem.* **2** (1994) 781–786; DOI: 10.1016/S0968-0896(00)82177-X.
10. S. Li, Z. Yao, Y. Zhao, W. Chen, H. Wang, X. Kuang, W. Zhan, S. Yao, S. Yu and W. Hu, Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase, *Bioorg. Med. Chem. Lett.* **22** (2012) 5279–5282; DOI: 10.1016/j.bmcl.2012.06.044.
11. F. E. Onen-Bayram, I. Durmaz, D. Scherman, J. Herscovici and R. Cetin-Atalay, A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells, *Bioorg. Med. Chem.* **20** (2012) 5094–5102; DOI: 10.1016/j.bmc.2012.07.016.
12. G. J. Atwell, C. D. Bos, B. C. Baguley and W. A. Denny, Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides, *J. Med. Chem.* **3** (1988) 1048–1052; DOI: 10.1021/jm00400a029.
13. G. J. Atwell, B. C. Baguley and W. A. Denny, Potential antitumor agents. 57. 2-phenylquinoline-8-carboxamides as minimal DNA-intercalating antitumor agents with in vivo solid tumor activity, *J. Med. Chem.* **32** (1989) 396–401; DOI: 10.1021/jm00122a018.
14. T. Suzuki, N. Fukazawa, K. San-nohe, W. Sato, O. Yano and T. Tsuruo, Structure activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer, *J. Med. Chem.* **40** (1997) 2047–2052; DOI: 10.1021/jm960869l.
15. Y. H. Wang, T. Motoji, S. Motomura, N. Shiozaki, T. Tsuruo and H. Mizoguchi, Multi-drug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line, *Eur. J. Haematol.* **58** (1997) 186–194; DOI: 10.1111/j.1600-0609.1997.tb00946.x.
16. H. Zhao, Y. Cai, S. Santi, R. Lafrenie and H. Lee, Chloroquine-mediated radiosensitization is due to the destabilization of the lysosomal membrane and subsequent induction of cell death by necrosis, *Radiat. Res.* **164** (2005) 250–257; DOI: 10.1667/RR3436.1.



17. H. Zhang, V. R. Solomon, C. Hu, G. Ulibarri and H. Lee, Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives, *Biomed. Pharmacother.* **62** (2008) 65–69; DOI: 10.1016/j.biopha.2007.04.007.
18. V. R. Solomon and H. Lee, Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies, *Eur. J. Pharmacol.* **625** (2009) 220–233; DOI: 10.1016/j.ejphar.2009.06.063.
19. M. S. Al-Said, M. G. El-Gazzar, M. S. Al-Dosari and M. M. Ghorab, Synthesis, anticancer activity and radiosensitizing evaluation of some new 2-pyridone derivatives, *Arzneimittel-Forsch.* **62** (2012) 149–156; DOI: 10.1055/s-0031-1299695.
20. P. Fossa, G. Menozzi, P. Dorigo, M. Floreani and L. Mosti, Synthesis and pharmacological characterization of functionalized 2-pyridones structurally related to the cardiotoxic agent milrinone, *Bioorg. Med. Chem.* **11** (2003) 4749–4759; DOI: 10.1016/S0968-0896(03)00528-5.
21. W. Chen, P. Zhan, D. Rai, E. De Clercq, C. Pannecouque, J. Balzarini, Z. Zhou, H. Liu and X. Liu, Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays, *Bioorg. Med. Chem.* **22** (2014) 1863–1872; DOI: 10.1016/j.bmc.2014.01.054.
22. M. M. Ghorab, Z. H. Ismail, M. Abdalla and A. A. Radwan, Synthesis, antimicrobial evaluation and molecular modelling of novel sulfonamides carrying a biologically active quinazoline nucleus, *Arch. Pharm. Res.* **36** (2013) 660–670; DOI: 10.1007/s12272-013-0094-6.
23. M. S. Al-Dosari, M. M. Ghorab, M. S. Alsaïd and M. Y. Nissan, Discovering some novel 7-chloroquinolines carrying a biologically active benzenesulfonamide moiety as a new class of anticancer agents, *Chem. Pharm. Bull.* **61** (2013) 50–58; DOI: 10.1248/cpb.c12-00812.
24. M. S. Alsaïd, M. S. Bashandy and M. M. Ghorab, Novel quinolines bearing a biologically active trimethoxyphenyl moiety as a new class of antitumor agents, *Arzneimittel-Forsch.* **61** (2011) 527–531; DOI: 10.1055/s-0031-1296239.
25. M. S. Bashandy, M. S. Al-Said, S. I. Al-Qasoumi and M. M. Ghorab, Design and synthesis of some novel hydrazide, 1, 2-dihydropyridine, chromene derivatives carrying biologically active sulfone moieties with potential anticancer activity, *Arzneimittel-Forsch.* **61** (2011) 521–526; DOI: 10.1055/s-0031-1296238.
26. M. M. Ghorab, M. S. Al-Said and E. M. El-Hossary, *In vitro* cytotoxic evaluation of some new heterocyclic sulfonamide derivatives, *J. Heterocycl. Chem.* **48** (2011) 563–571; DOI: 10.1002/jhet.619.
27. M. S. Al-Said, M. S. Bashandy, S. I. Al-Qasoumi and M. M. Ghorab, Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives, *Eur. J. Med. Chem.* **46** (2011) 137–141; DOI: 10.1016/j.ejm-ech.2010.10.024.
28. M. M. Ghorab, F. A. Ragab, H. I. Heiba, R. K. Arafa and E. M. El-Hossary, Docking study, in vitro anticancer screening and radiosensitizing evaluation of some new fluorine-containing quinoline and pyrimidoquinoline derivatives bearing a sulfonamide moiety, *Med. Chem. Res.* **20** (2011) 388–400; DOI: 10.1007/s00044-010-9332-3.
29. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenny and M. R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, *J. Natl. Cancer. Inst.* **82** (1990) 1107–1112; DOI: 10.1093/jnci/82.13.1107.
30. M. M. Ghorab, M. S. Alsaïd, H. A. Ghabour and H.-K. Fun, Synthesis, crystal structure and anti-tumor activity of novel 2-cyano-*N*-(quinolin-3-yl) acetamide, *Asian J. Chem.* **26** (2014) 7389–7392; DOI:10.14233/ajchem.2014.17050.